Compare Globus Medical Inc. Class A Common Stock (GMED) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Vistra Corp — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Vistra Corp trades at $148.1 (market cap $50.95B). The key difference: Vistra Corp is far larger — about 5× Globus Medical Inc. Class A Common Stock's market cap, and Vistra Corp pays a 0.61% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Vistra Corp for 33 Days on average.
| GMED | VST | |
|---|---|---|
Market Cap | $10.25B | $50.95B |
Volume | 1,059,528 | 7,315,402 |
Sector | Health | Utilities |
52-Week High | $96.82 | $210.85 |
52-Week Low | $58.33 | $134.71 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $9.76B | $72.88B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Vistra Corp (VST) trades at $162.36, up 2.68% with strong institutional support and bullish technical indicators. The stock shows impressive profitability with 75.73% ROE and 11.55% net margin, though recent earnings were mixed with Q1 beat but Q2 miss. Recent developments include a $4.2 billion government loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning VST to capitalize on AI-driven electricity demand.
Vistra presents significant upside potential with a $215.23 consensus price target (32.5% upside) and 91.3% buy ratings. The company benefits from nuclear power expansion and AI infrastructure demand, though risks include execution of growth initiatives and energy market volatility. Current valuation at 27.38 P/E appears reasonable given growth prospects in the power generation sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
